Astera Labs, Inc. $ALAB Stock Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC reduced its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) by 27.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 184,321 shares of the company’s stock after selling 70,675 shares during the quarter. Stephens Investment Management Group LLC owned approximately 0.11% of Astera Labs worth $65,613,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Astera Labs during the 2nd quarter worth about $6,609,581,000. ABS Investment Management LLC bought a new position in shares of Astera Labs during the second quarter worth approximately $1,980,382,000. Van ECK Associates Corp grew its holdings in Astera Labs by 20.0% in the 2nd quarter. Van ECK Associates Corp now owns 2,237,961 shares of the company’s stock valued at $1,080,980,000 after buying an additional 373,545 shares in the last quarter. Bank of America Corp DE bought a new position in Astera Labs during the 2nd quarter worth $1,061,791,000. Finally, Atreides Management LP acquired a new stake in shares of Astera Labs during the second quarter worth $587,736,000. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Stock Up 2.4%

NASDAQ:ALAB opened at $216.75 on Thursday. The firm has a market capitalization of $37.88 billion, a PE ratio of 86.35 and a beta of 3.85. Astera Labs, Inc. has a twelve month low of $97.89 and a twelve month high of $499.48. The stock’s 50-day simple moving average is $288.88 and its 200 day simple moving average is $257.84.

Astera Labs (NASDAQ:ALAB – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.13. The company had revenue of $584.90 million for the quarter, compared to analyst estimates of $550.78 million. Astera Labs had a net margin of 29.64% and a return on equity of 25.35%. The firm’s revenue was up 153.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.49 EPS. On average, analysts anticipate that Astera Labs, Inc. will post 2.99 EPS for the current fiscal year.

Insider Buying and Selling at Astera Labs

In related news, Director Manuel Alba sold 183,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the sale, the director owned 253,863 shares in the company, valued at $71,114,642.19. The trade was a 41.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stefan Dyckerhoff sold 8,994 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $211.41, for a total value of $1,901,421.54. Following the completion of the transaction, the director owned 1,987 shares of the company’s stock, valued at $420,071.67. This represents a 81.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 417,090 shares of company stock worth $102,663,347 over the last three months. 10.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ALAB has been the topic of a number of recent research reports. Zacks Research lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. BMO Capital Markets began coverage on shares of Astera Labs in a research report on Thursday, November 5th. They issued an “outperform” rating and a $375.00 price target for the company. Roth Capital reiterated a “buy” rating and issued a $450.00 price target on shares of Astera Labs in a research note on Wednesday, August 5th. Wall Street Zen upgraded Astera Labs from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Susquehanna dropped their price objective on Astera Labs from $310.00 to $258.00 and set a “neutral” rating for the company in a report on Wednesday, November 4th. Thirteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Astera Labs has an average rating of “Moderate Buy” and an average price target of $320.85.

Read Our Latest Analysis on Astera Labs

Astera Labs News Summary

Here’s some of the latest news about ALAB:

Astera Labs Profile

(Free Report)

Astera Labs, Inc. is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems. The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.

Recommended Stories

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.